| Followers | 26 |
| Posts | 2781 |
| Boards Moderated | 0 |
| Alias Born | 03/18/2013 |
Saturday, January 14, 2023 11:14:56 AM
Unbelievable; you dudes can stroke each others libido all you want. You know JesseLivermore warned us of not selling out to Big Pharma. Well, that was before the avalanche hit us.
If you think management has done a good job think again. Good job at what? Milking the company and shareholders out of stock options and rewarding themselves wonderful salaries. What have they done really? Only when Alex Denner had the cahones enough to call them out on their lavish lifestyles and bumbling of European acceptance of Vascepa.
Karim made a lot of promises which he hasn't kept. He's hired his old cronies and made sure they were paid well with no accountability and performance goals. Must be pretty nice to live in Zug, Switzerland on a $5 million + a year salary plus stock options. The "silence" is deafening. The non-communication is enough for me to cast my shares for Denner.
Only when approached with the threat of losing their jobs, have they decided to throw the shareholders a bone "with no meat." Show me the money
What is your plan? Because I don't think management has a plan. They still want to go it alone it. This is ludicrous. No partners, all lip service. This drug has a time value. The more time wasted the less chance we have of recovering our investment. Plain and simple.
The only reason the share price has gone up is because of Denner and those familiar with his track record have been buying shares in anticipation of what's about to happen. Denners plan is simple. Find a buyer, negotiate a decent price, do the deal.... Done, we're outta here.
Hopefully, its with a company that has a need for a great drug and pays a good dividend.
If you think management has done a good job think again. Good job at what? Milking the company and shareholders out of stock options and rewarding themselves wonderful salaries. What have they done really? Only when Alex Denner had the cahones enough to call them out on their lavish lifestyles and bumbling of European acceptance of Vascepa.
Karim made a lot of promises which he hasn't kept. He's hired his old cronies and made sure they were paid well with no accountability and performance goals. Must be pretty nice to live in Zug, Switzerland on a $5 million + a year salary plus stock options. The "silence" is deafening. The non-communication is enough for me to cast my shares for Denner.
Only when approached with the threat of losing their jobs, have they decided to throw the shareholders a bone "with no meat." Show me the money
What is your plan? Because I don't think management has a plan. They still want to go it alone it. This is ludicrous. No partners, all lip service. This drug has a time value. The more time wasted the less chance we have of recovering our investment. Plain and simple.
The only reason the share price has gone up is because of Denner and those familiar with his track record have been buying shares in anticipation of what's about to happen. Denners plan is simple. Find a buyer, negotiate a decent price, do the deal.... Done, we're outta here.
Hopefully, its with a company that has a need for a great drug and pays a good dividend.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
